Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Supernus Pharma (SUPN) Reports Q4 EPS of $0.04
April 13, 2022 4:13 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.04, versus $0.57 reported last year. Revenue for the quarter came in at $159.1 million, versus $143.6 million reported last year.
GUIDANCE:
Supernus Pharma sees FY2022 revenue of $640-680 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
... More